
 
 
 
 
 
 
 
 
   
 1. A chimeric antigen for eliciting an immune response, said chimeric antigen comprising an immune response domain and a target binding domain, wherein the immune response domain comprises one or more antigenic portions 5 of a protein from HCV, HPV, HIV, HSV, an obligate intracellular parasite or a cancer antigen and the target binding domain comprises a xenotypic Fc antibody fragment, wherein the antibody fragment comprises an immunoglobulin heavy chain fragment comprising all or a part of an antibody fragment selected from the group 10 consisting of the CH1, the hinge region, the CH 2 domain, and the CH 3 domain, and wherein the chimeric antigen is glycosylated.  
 
     
 2. The chimeric antigen of claim 1, wherein the chimeric antigen elicits a humoral immune response, a cellular immune response, or a both humoral immune response and a cellular immune response. 15 
 
     
 3. The chimeric antigen of either one of claims 1 or 2, wherein the chimeric antigen elicits a Th1 immune response, a Th2 immune response or both a Th1 and a Th2 immune response.  
 
     
 4. The chimeric antigen of any one of claims 1 to 3, wherein the immune response is an in vivo immune response. 20 
 
     
 5. The chimeric antigen of any one of claims 1 to 4, wherein the immune response domain comprises more than one protein.  
 
     
 6. The chimeric antigen of any one of claims I to 5, wherein the immune response domain comprises one or more immunogenic portions of one or more proteins selected from the group consisting of a HCV Core (1-191) protein, a HCV Core 25 (1-177) protein, a HCV p7 protein, a HCV El protein, a HCV E2 protein, a HCV El-E2 protein, a HCV NS3 protein, a HCV NS4B protein, and a HCV NS5A protein.  
 
     
 7. The chimeric antigen of any one of claims 1 to 5, wherein the immune response domain comprises one or more immunogenic portions of one or more 30 Plasmodium proteins.  
 
     
 8. The chimeric antigen of any one of claims 1 to 5, wherein the immune response domain comprises one or more immunogenic portions of one or more HIV proteins. 239 
 
     
 9. The chimeric antigen of any one of claims 1 to 5, wherein the immune response domain comprises one or more immunogenic portions of one or more cancer antigen proteins.  
 
     
 10. The chimeric antigen of any one of claims 1 to 9, wherein the target binding 5 domain is capable of binding to an antigen presenting cell (APC).  
 
     
 11. The chimeric antigen of any one of claims 1 to 10, further comprising one or more of a 6xHis tag, a protease cleavage site, and a linker for linking the immune response domain and the target binding domain.  
 
     
 12. The chimeric antigen of claim 11, wherein the linker is selected from the group 10 consisting of leucine zippers, biotin bound to avidin, and a covalent peptide linkage.  
 
     
 13. The chimeric antigen of any one of claims 1 to 12, wherein the chimeric antigen is mannose glycosylated.  
 
     
 14. A method of delivering an antigen to an antigen presenting cell, the method 15 comprising administering to the antigen presenting cell a chimeric antigen of any one of claims I to 13.  
 
     
 15. The method of claim 14, wherein the antigen presenting cell is a dendritic cell.  
 
     
 16. A method of activating an antigen presenting cell, the method comprising contacting the antigen presenting cell with a chimeric antigen of any one of 20 claims I to 13.  
 
     
 17. The method of claim 16, wherein the contacting takes place ex vivo.  
 
     
 18. The method of claim 16, wherein the contacting takes places in vivo.  
 
     
 19. The method of claim 18, wherein the contacting takes place in a human.  
 
     
 20. The method of either one of claims 18 or 19, wherein the method comprises 25 administering to a subject a composition comprising a chimeric antigen of claim 1, and wherein the antigen presenting cell is in the subject.  
 
     
 21. The method of any one of claims 17 to 20, wherein the contacting results in a humoral immune response, a cellular immune response, or both a humoral immune response and a cellular immune response. 30 
 
     
 22. The method of claim 21 wherein the cellular immune response is one or more of a Thi response, a Th2 response, and a CTL response.  
 
     
 23. The method of any one of claims 20 to 22, wherein the subject has, or is likely to have, an immune-treatable condition. 240 
 
     
 24. The method of claim 23, wherein the immune-treatable condition is an acute infection.  
 
     
 25. The method of claim 23, wherein the immune-treatable condition is a chronic infection. 5 
 
     
 26. The method of claim 25, wherein the chronic infection is a chronic hepatitis C viral infection.  
 
     
 27. The method of any one of claims 23 to 26, wherein the immune-treatable condition is a hepatitis C viral infection and the immune response domain comprises one or more antigenic portions of one or more proteins selected from 10 the group consisting of a HCV Core (1-191) protein, a HCV Core (1-177) protein, a HCV El protein, a HCV E2 protein, a HCV El -E2 protein, a HCV P7 protein, a HCV NS3 protein, a HCV NS4B protein, and a HCV NS5 A protein.  
 
     
 28. The method of any one of claims 20 to 27, wherein the subject is vaccinated against a viral infection. 15 
 
     
 29. The method of any one of claims 20 to 28, wherein the subject is prophylactically vaccinated against a viral infection.  
 
     
 30. The method of either one of claims 28 or 29, wherein the subject is therapeutically vaccinated against an existing viral infection.  
 
     
 31. A method of producing the chimeric antigen of any one of claims I to 13, 20 comprising: (a) providing a microorganism or a cell, the microorganism or cell comprising a polynucleotide that encodes the chimeric antigen; and (b) culturing said microorganism or cell under conditions whereby the chimeric antigen is expressed. 25 
 
     
 32. The method of claim 31, wherein the microorganism or cell is a eukaryotic microorganism or cell.  
 
     
 33. The method of either one of claims 31 or 32, wherein the cell is a yeast cell, a plant cell or an insect cell.  
 
     
 34. The method of any one of claims 31 to 33, wherein the chimeric antigen is post 30 translationally modified to comprise glycosylation.  
 
     
 35. The method of any one of claims 31 to 34, wherein the chimeric antigen is post translationally modified to comprise a mannose glycosylation.  
 
     
 36. A polynucleotide encoding a chimeric antigen of any one of claims 1 to 13, said polynucleotide comprising a first polynucleotide portion encoding an immune 35 response domain and a second polynucleotide portion encoding a target binding domain, wherein the immune response domain comprises one or more antigenic 241 portions of a protein from HCV, HPV, HIV, HSV, an obligate intracellular parasite or a cancer antigen and the target binding domain comprises an antibody fragment.  
 
     
 37. The polynucleotide of claim 36, wherein the antibody fragment is a xenotypic 5 antibody fragment.  
 
     
 38. A vector comprising the polynucleotide of either one of claims 36 or 37.  
 
     
 39. The vector of claim 38, wherein the polynucleotide is operably linked to a transcriptional regulatory element (TRE).  
 
     
 40. A microorganism or cell comprising the polynucleotide of either one of claims 36 10 or 37.  
 
     
 41. An article of manufacture comprising a chimeric antigen of any one of claims 1 to 13 and instructions for administering the chimeric antigen to a subject in need thereof  
 
     
 42. A pharmaceutical composition comprising a chimeric antigen of any one of 15 claims 1 to 13 and a pharmaceutically acceptable excipient.  
 
     
 43. A method of producing the chimeric antigen of any one of claims 1 to 13, comprising: (a) providing a microorganism or a cell, the microorganism or cell comprising a polynucleotide that encodes a target binding domain-linker molecule, wherein the 20 target-binding domain-linker molecule comprises a target binding domain bound to a linker molecule; (b) culturing said microorganism or cell under conditions whereby the target binding domain-linker molecule is expressed; and (c) contacting the target binding domain-linker molecule and an immune response 25 domain under conditions that allow for the binding of the linker to the immune response domain, the binding resulting in a chimeric antigen.  
 
     
 44. A chimeric antigen for eliciting an immune response; and/or a method of delivering an antigen to an antigen presenting cell; and/or a method of activating an antigen presenting cell; and/or 30 a method of producing a chimeric antigen; and/or a polynucleotide encoding a chimeric antigen; and/or a vector comprising the polynucleotide; and/or a microorganism or cell comprising the polynucleotide; and/or an article of manufacture comprising a chimeric antigen; and/or 35 a pharmaceutical composition comprising a chimeric antigen; substantially as herein described with reference to any one of the embodiments of the invention illustrated in the accompanying drawings and/or examples. 242 
 
   
 
 
 
 
 
 
 
 
